KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Construction in Progress (2017 - 2018)

Historic Construction in Progress for Alnylam Pharmaceuticals (ALNY) over the last 6 years, with Q4 2018 value amounting to $261.0 million.

  • Alnylam Pharmaceuticals' Construction in Progress rose 9527.48% to $261.0 million in Q4 2018 from the same period last year, while for Dec 2018 it was $261.0 million, marking a year-over-year increase of 9527.48%. This contributed to the annual value of $261.0 million for FY2018, which is 9527.48% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Construction in Progress of $261.0 million as of Q4 2018, which was up 9527.48% from $133.6 million recorded in Q4 2017.
  • Alnylam Pharmaceuticals' Construction in Progress' 5-year high stood at $261.0 million during Q4 2018, with a 5-year trough of $1.3 million in Q4 2015.
  • In the last 4 years, Alnylam Pharmaceuticals' Construction in Progress had a median value of $67.8 million in 2014 and averaged $99.5 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Construction in Progress skyrocketed by 697857.14% in 2014 and then tumbled by 3516.65% in 2015.
  • Over the past 4 years, Alnylam Pharmaceuticals' Construction in Progress (Quarter) stood at $2.0 million in 2014, then crashed by 35.17% to $1.3 million in 2015, then surged by 10300.39% to $133.6 million in 2017, then skyrocketed by 95.27% to $261.0 million in 2018.
  • Its last three reported values are $261.0 million in Q4 2018, $133.6 million for Q4 2017, and $1.3 million during Q4 2015.